Key Takeaways

Oculus has introduced "Meibo Analytics," a new artificial intelligence-assisted decision-support tool for the Keratograph 5M designed to help clinicians evaluate meibomian gland dysfunction (MGD).

The software uses AI-driven image analysis to quantify meibography images and support clinicians in interpreting structural changes in the meibomian glands.

According to Oculus, unlike functional tests alone, meibography provides structural insights into gland health that can help clinicians identify disease progression. However, interpreting these images can be subjective, particularly in the early and intermediate stages of MGD. Studies have shown variability in how clinicians interpret meibography findings, even among experienced examiners. Oculus said the challenge lies less in image acquisition and more in achieving consistent interpretation of results.

Meibo Analytics was developed to address those inconsistencies by applying AI-based structure analysis to meibography images. Integrated into the company’s JENVIS Pro Dry Eye Report, the tool is designed to evaluate gland morphology according to the Arita grading scale, assessing gland dropout and overall gland structure.

The company said the goal is not to replace physician judgment, but rather to provide a standardized and reproducible classification system that can reduce diagnostic uncertainty and improve confidence during evaluations.

By combining conventional meibography with automated image analysis, Meibo Analytics is intended to support more structured and consistent MGD diagnostics in routine clinical practice, Oculus stated.

More information about Meibo Analytics and the Keratograph 5M is available here.